1626 related articles for article (PubMed ID: 36438201)
1. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
2. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
3. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
Li Y; Zeng X
Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
[No Abstract] [Full Text] [Related]
4. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
[TBL] [Abstract][Full Text] [Related]
5. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
6. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
7. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
Wang X; Chen D; Shi Y; Luo J; Zhang Y; Yuan X; Zhang C; Shu H; Yu W; Tian J
Front Immunol; 2023; 14():1123231. PubMed ID: 37153542
[TBL] [Abstract][Full Text] [Related]
8. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
Front Genet; 2023; 14():1056000. PubMed ID: 36845390
[No Abstract] [Full Text] [Related]
9. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
Front Genet; 2023; 14():1094793. PubMed ID: 36891150
[No Abstract] [Full Text] [Related]
10. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma.
Wang J; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Qin D; Zhong S; Hu X
Front Oncol; 2023; 13():1152681. PubMed ID: 37333810
[TBL] [Abstract][Full Text] [Related]
11. Pyroptosis related genes signature predicts prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.
Fang G; Zhang Q; Fan J; Li H; Ding Z; Fu J; Wu Y; Zeng Y; Liu J
BMC Cancer; 2022 Sep; 22(1):999. PubMed ID: 36127654
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
[TBL] [Abstract][Full Text] [Related]
13. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
14. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
Jiang H; Chen H; Wang Y; Qian Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
[TBL] [Abstract][Full Text] [Related]
15. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
16. Cuproptosis-related molecular classification and gene signature of hepatocellular carcinoma and experimental verification.
Chen Z; Du D; Li J; Zhang W; Shao J
Transl Cancer Res; 2024 Mar; 13(3):1268-1289. PubMed ID: 38617510
[TBL] [Abstract][Full Text] [Related]
17. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
Yan C; Niu Y; Ma L; Tian L; Ma J
J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
[TBL] [Abstract][Full Text] [Related]
18. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features.
Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090
[TBL] [Abstract][Full Text] [Related]
19. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
Front Immunol; 2022; 13():919231. PubMed ID: 35967366
[TBL] [Abstract][Full Text] [Related]
20. Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC.
Wang Y; Zhang Y; Wang L; Zhang N; Xu W; Zhou J; Zhao Y; Zhu W; Zhang T; Wang L
Hepatol Int; 2022 Dec; 16(6):1435-1447. PubMed ID: 36065073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]